ALBO - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and thank you for joining us for Albireo's Conference Call to provide a Business Update for the First-Half of 2018.

Following some prepared remarks from the company, we'll open the call for questions. I would now like to turn the call over to Paul Arndt from LifeSci Advisors, representing Investor Relations for the company. Please go ahead, sir.

Paul Arndt

Thank you, Operator, and good morning everyone. today's Albireo's which of performance joining an will XXXX. for on update in you call management during provide Thank the first-half accomplishments six-month period Earlier highlighting June XX, results a issued ended the and business for and today, financial noting quarter press second XXXX. its Albireo recent release site press The Web is via accessible www.albireopharma.com. release company's the at

proceeding, me mention Act forward-looking the under made Litigation let that Reform include Before Private XXXX. of statements comments today Securities may

program, the statements required of Forward-looking or candidate plans or place you endpoints, statements the reliance XX-K or or regarding regulatory including the design, relied other duration, timing size, factors for fillings historical or for only development, Factors feedback regarding date. of development or result any Tuesday, initiation of Albireo's than scope, of, results Officer. on of any the include as Statements AXXXX, today, X, from, Risk any of, duration cost, many Also, target product prevalent reporting from Chief or as indications clinical progress, Ron or or fact for for statements Forward-Looking AXXXX, other objective, implied population, location, results conduct, completion should forward-looking data, With I'll speaks Form statement, Albireo its of commercial elobixibat, candidate operations, obligation Albireo's expressed to patients from made of expectations or undue as any and any planned differ including in any SEC. not in or sufficient that, fund those by target indication, make as over the cash that with X additional product those Albireo AXXXX or any Pharma update any operating or may any to most with today, statement resources and by release Albireo payment period costs materially the trial turn position, statement PFIC, results August forward-looking as recent financial later or forward-looking earlier in to Executive the to HealthCare for Actual future the Royalty any XXXX requirements, under which trial, Partners Phase applicable not revenues, upon is opportunity Albireo's program will for future EA be or a Albireo, may the its expenses. outlook Albireo's Ron? plans, press forward-looking except President disclaims described and representing in Albireo be any heading to including cautions that Albireo's statement. Albireo's in views call law. under Cooper, heading or

Ron Cooper

curious appointments. today that everybody really Chief Thank Mattsson, Albireo's and you, for at I'm today's position Albireo striking Tom one two, call. for asset three, Financial AXXXX AXXXX; Paul, assets; serious organization of Chief our and progress preparing rare our patent in and and across we've Albireo's our thank With key conference of diseases; by, Co-Founders. Officer; me significant QX made one, and the is liver our joining Officer lead regulatory advancing strengthening the you Jan four, for Operating of with and pediatric excited Shea, commercialization [ph] development

quarter your significant Phase milestone items, into first X trial in further a these the patient achieved these by progressive intrahepatic on PEDFIC-X, expand me familial of Albireo the detail questions be AXXXX, happy let and we'll our enrolling Advancing to cholestasis greater Now, each or topics. with PFIC. in go second clinical on

of response. a with trial trial X long-term open primary for and the new two approximately The a study story for randomized to durability the are doses pruritus a a PFIC quick extension an XX AXXXX EMA placebo-controlled X, FDA enroll designed placebo-controlled the or those EMA The rate. assess key type X for AXXXX of The here's secondary will you is the Phase patients to endpoint synopsis. endpoint is double-blind endpoint a single in for for clinical program label includes Now secondary evaluation and acid the who a safety multicenter type and key developed. and tool endpoint FDA serum weeks. evaluate trial's we primary The bile change XX for of using proprietary to responder

the the continues July. activate And we're in Europe. to to the trial the at following U.S. around investigators for work clinical and meeting activated expeditiously XX sites well activation site world Our track now of end all in on Europe in the of U.S. attended very with sites team and

to we refine we to and that closer. available XXXX guided, get we guidance or of end the As around XXXX, continue we as plan be previously expect to data early

our addition, impact outcomes we patients. Provided data trial, congresses in the outcomes developing for observer-reported tools of strengthen that X have PFIC AXXXX. early insights released liver the patient-reported for evaluate utility of Phase the were predicting negative pediatric the biomarkers support certain that in long-term at efficacy and on used for life on creation quality of the Now, outcomes and in of both scientific key profile diseases the and

in for treatment included regulatory redeemed we for patent to marketing enhanced that this dialogue EMA study Europe. granted the to meeting announce our the NASH. front, the to of was rapporteur. submission priority is X priority upon FDA subsequent very A elobixibat or were We'd and we kickoff participated the assessment in at to designation I'm be is that, in This the Medicines June, maybe an in of that a for obtaining of another PFIC. a method review NASH granted In of and items patent asset company disclosed MEdicines and both confident gating our initiating in European application. for for for On rate or apply Agency use the our U.S. transferred June, Phase AXXXX voucher with voucher the review the PRIME pediatric pleased medicines. NDA. affirms previously patent that disease one obtain PRIority of a designation sold PRIME accelerate priority molecule valuable or that to announced provides another eligibility a for priority review can we

our reiterating first-half trial we XXXX. anticipate of are in guidance initiating the We that this

Now need and commercialization. writing have to now PEDFIC-X the we potential going, that and and for we filings begin up approval AXXXX the this study regulatory for

the on For safety track, long-term are toxicology preparations manufacturing overall filings, studies. preparations and including and

deployment part buildup we commercialization, science started of appointed the liaisons. having the For initiated medical and early marketing ahead of of

of year, in insights a of pieces the level paucity of cholestatic and liver research to assessment AXXXX, size, we're today the take patient population related parents of disease completed of there's rare to insight and and share overall research interest to aware AXXXX, and better of Europe, opportunity Unfortunately liver the we've physician and pediatric of research qualitative gathering The and encompassing view opportunity. high-level additional quantitative We children with of conducted In also U.S. PFIC secondary to emerging study the any diseases, reaction patient price market with the comparators. the early couple to first-half with gain this a of of we liver been results studies wanted the and to the We physicians the with research and journey, patient not in scoping the treat disease, States prevalence along deeper physicians PFIC. this of in liver of for United cholestatic our size population market opportunity a cholestatic on disease contribute PFIC an who literature pricing on registries. in analogues. cholestatic potential

recently we completed a that pediatric treat cholestatic As disease, size at adult in the result, diseases, available have other the research. of others. cause resources, market look three We liver liver using patient liver and in for potential agent opportunity secondary and fibrosis modeled population as and cholestasis disease cystic an such diseases may the literature, areas, to

AXXXX for While development focus diseases. we see chosen pediatric AXXXX we've to diseases, of the a in liver many tremendous cholestatic on opportunity

that. are primary estimate market initial the liver Our agent range secondary And years, and prevalence is narrowed about to we've a on XX,XXX data refine experts and smaller. our benign we patients, BRIC the continue atresia average manifest and of understanding estimate Alagille lager, a in is there on our and XX,XXX Most Based the would research about defect to research the based the BRIC of incidence prevalence. patients had survival, U.S. survival cholestatic patients BRIC, with this same this We PFIC, E.U. whereas range investigational suggest We've symptoms, us episodic we the targets, intrahepatic the benign and genetic [ph]. BRIC for really BRIC term PSC as in recurrent are to and severe for the and of diseases patients as interest with XX have double pruritus. to estimate same that Alagille, XX,XXX PFIC about mix on PFIC, or it's cholestatic PFIC that together different patients diseases liver atresia, including range, for our primary initially biliary adjusted same particularly now PFIC biliary the to to and XX,XXX for misnomer. cholestasis XX,XXX X,XXX

market including developing and challenge, clinical our areas, types we're cholestatic these AXXXX biliary in syndrome, X outlook. We of rare Alagille potentially confidence primary but X will continue and enrolling PFIC estimates As believe to and diseases other atresia, you're Having Phase with in useful data generation aware, we're cholangitis. exploring these only is trial population us assessing gives And insight sclerosing X. development, our a ultimately these patients remain diseases. gradually precise prove of address to the could

Medical Harvard and And professor to let our and with is commercialization pleased diseases pleased Senior HealthCare, organization, I'm former year Medical orphan Officer. Officer School, call important of a announced North Okey down our strengthen as our has So new America all for in Chief Jason deeper the Counsel. at Soni I Board of our work, on Paresh stage hand to School. first-half regulatory the the over and Genzyme. take want also Rare Harvard years been his X(X) recently company. bring will Academic before instrumental as the I'm General design, over of additions of PEDFIC-X of very as the he's addition in board. this I we've update with thank for our and deep welcome We're to contributions the past approval company. Directors. stepped building the dean Horn medicine is Partners the on process, Chief be HealthCare Paresh growth Klibanski to Head the insights of the Patrick and the background trial, of Pat Phase important he to hard an at currently Officer Vice me Medical excited as President consultant real and opportunity integral Medical Anne that for stay We will as to enter by regulatory to financials, been but to his to where succeeded Duncan an next close Diseases immensely to outstanding key Both into Chief we delighted and Anne that welcome really the Stephanie been and at as appointments and initiation and organization. the our an Partners discuss academic Stephanie pediatric Tom experience

now Tom? hand update. financial to call I'll the Okay, over Tom quick a for

Tom Shea

Thanks, Ron.

results XX, $XXX.X compared Let quickly ended cash $XX.X balance and XX, XXXX financial second our June of today. June We cash months released for million three to ending at me XXXX. we which in a and December equivalents closed XX, six the earlier XXXX, with million highlight quarter

and second the six for XXXX. $XXX,XXX for $XX.X Our quarter ended of XX, months million XXXX was June revenue the

development second expenses million compared same XXXX XXXX. for the to of $X quarter XX, of of research million compared the June the XXXX was six were $X.X in Our to $X.X million XXXX. expenses months million quarter second $XX.X the R&D for and in period ended

operating quarter million expenses expenses to G&A for million compared XX, $X.X $X.X XXXX was ended expect million a per of were we $X.X expected the AXXXX. period six-month of of sharein XX, or period for $XX G&A the million into driven share was be our million loss Phase $XX.X second of XXXX June second share primarily quarter loss our standpoint, current million $XX.X to our the current XXXX. range sufficient XXXX. XXXX for in six to of $X.XX the $X.XX of Net over six $XX quarter Net plan. of with clinical months current expenses the meet compared $X.XX ended From the in the on to six-month study under ended cash XXXX increase or a million a or our operating Based second the resources Our $X.X X in XXXX the of to XXXX. $X.X per in million the we XX, $X.XX net operating per same XXXX. compared in to loss a share global anticipate loss compared same was or million of of XXXX $XX.X per months million to plans, execution by XXXX net requirements quarter second June our the for be will June

concluding call of stock early for back upcoming or indication a reflect initiation XXXX NASH, of indexes. elobixibat our and as with planned XXXX. And events X of Russell for Ron remarks. a not BAM of with for let Index PFIC guidance and we over expected some annual changed second the conclusion at AXXXX And in that Phase Our of AXXXX the the data all XXXX. line Top XXXX me end from the Russell part important finally, in have to turn the trial is and reconstitution trials

Ron Cooper

you, Thank Tom. Great.

now, same we So understanding PFIC That the data time and to At summarize, be right PFIC, and our therapy potential we'll to advancing our Phase core our that tremendously understanding to is and broader X remain of continue I present new to pipeline. to hope our focus PFIC bringing market. to excited for add we advancing their people with strengthen the of families. the with along continue trial

Okay.

questions. that open with So call we'll Operator? up the to

Operator

Jefferies. conduct time Our proceed question. first comes your Thank session. you. from Yang At Eun this with a with [Operator question question-and-answer we Instructions] will Please

Eun Yang

Thank you.

some on do think the number need build? based and pre-commercial a targeted you many of how done since [ph], activities, would size acquisitions you market have Ron, the sales So of reps to you

Ron Cooper

morning, good Yes, Eun, for thanks question. the

in if the the we market and scope target of probably actually do And of D things from a with I around audience you target there B, X,XXX, out to then audience. the size look, U.S., our targets. XXX another that the is perspective just one started think targets C, are research A to

highly concentrated, also highly centers. concentrated and So the in tertiary

the we to now there So about. I we're deployed the of think a we U.S. and on individuals. would to deployed, that really still in starting innovative field term effectively, to we're think between somewhere reason going deploy Europe the the range use what model is way we're probably that's our XX think can we're and XX looking I at And thinking both about deploy. field target We be how but

Eun Yang

are XX So the -- XX then that number the in U.S. and in same ones to approximately Europe?

Ron Cooper

Yes, approximately, about the same.

think So it, in that's about it's the Europe. a way we amount similar

Eun Yang

the liver mentioned you to XX,XXX then the with only And patients pediatric patients, correct? Okay. that XX,XXX disease, cholestatic to refers

Ron Cooper

U.S. footprint do this that us changed we've case. pretty we've to of so And been range XX,XXX some that, So, and And market that at XX,XXX secondary about to to comes just We've XX,XXX. guiding in previously sources. helped literature also mostly and range a tightened interesting so range. a patients the that's we've Europe XX,XXX and why corrections couple that's to from able research of refine to -- a in wider been about

So so America of because all at difficult world, the Japan, and it's we Canada, rest get to haven't data, really that Asia. the Latin looked

then that So takes population and time. XX,XXX for a with the have to given the both us the we number pediatric XX,XXX at adults

Eun Yang

great, Okay, thank you.

Ron Cooper

that clarifies? Hopefully,

Eun Yang

of [indiscernible] next of by XX are this the in to about be so million, sites and then year or end remark, to you Tom, the Ron's I expenses And like at one remaining, operating but for $XX the thanks. activated activate year. to the you Yes, XX $XX know, about to you mentioned question that July there million expect then the to end think

this the second-half of uptick So expect you in R&D expenses don't for year? really

Tom Shea

a associated No, over the once it's running, pretty be subject. have to recruit of startup there and the actively and spread quarters, up getting evenly are because going lot trial Eun, ongoing expenses with start to we the expense, the you then

over quarters. the So out, it's evenly spread worked as to be fairly it going

so coming in anticipate So or we $XX range. do million at

Eun Yang

Great, much. thank you very

Tom Shea

You're welcome.

Operator

from your question. proceed William Our Xu comes Katherine Blair. with Please next with question

Katherine Xu

by whether Yes, on sites sort good end is give Ron, -- of just morning. that ahead frame of track, and on of around color that XX opened And would I was just us in wondering some the the the expectations, of could next you, give July, the helpful. the really what study, step some expectations? sites sentiments at is maybe the general, be

Ron Cooper

good Yes, for the and morning, Katherine, thanks question.

that to I some unbelievable. think, with investigators with that relieved excitement we've cooperation enjoyed I've number get site going, from going. we're the of the they're just to sites start the [indiscernible] and been of been with, for waiting and our us and and receiving and notes really been their the has excellent. They've a study investigators those fair up is up

they're So cooperating with us.

lot study will being we is protocol, is is the Now a the touches so we anticipate XX And to XX you know, protocol, XX it this countries. the said, that but it having take itself pharmacy, between it -- complicated sites, imaging. of in over have to well-written blood, be because to institution, that from parts a right, clinical everything every a somewhere protocol a we

we try of get a as chunk in those it's work. So fair and sites, approvals of each

have we So then where you is of on expecting. that track XX going the to sites actually what characterize up we're we much pretty and know, are,

And working with hard through way working get the of we've get now some to other patients want sites they going. because to coming our got things are get and right IRBs, the possible. sites, the We that process the those up focus the of But those to work to quickly as in. is as contract months,

Katherine Xu

[indiscernible] past more quarter information the give with you And and about incrementally that? program, the the to then on NASH regard have some just of potential maybe over indication learned Thanks. us what

Ron Cooper

for the thanks question, Well, Katherine.

in we the things; that year are -- I all said of against we earlier gated I the program was had patent, first think right. the development NASH think one that the

hand let little to talk Jan excited about talk bit a that about So me about over then maybe from I'll NASH to and are a we perspective. it what

that on patent. it So was were and we for pretty said that. of confident going we about [ph] start to use We method had believe didn't rate were that waiting limiting a be we the

fact, quarter the achieve announced receipt we we in patent. of this in that that So did

program? on a are So we're we're to Jan, and we that NASH with about want talk maybe about you the delighted little bit track. where

Jan Mattson

sure. Sure,

learned tremendous the more to just had in bile acid been group, recently action that are increased know So movement in NASH. example, acid you bile field and a that to we what there's say showing may as half Sanyal's last from -- year not in with NAFL patients for

we we we clinical So doses showing affect our of and the as is NASH. have you data know as in cholesterol. better, key we're COB little increased lowering inflammation, are X before which markets confident We us of our

protocol And and starting KOLs our so for are we the to studies. with engaged guess are

and where that's next So we we first-half [indiscernible] us for year. are said, to guiding as

Ron Cooper

So track. we're on

Katherine Xu

general Okay. single-arm And is cetera, kind have think assuming study? lastly, of I'm the on of or you that PFIC development you population, the single Do some work plan successful. a just studies to wondering extension do labor would PFIC trial of X think X kind thought et clinical AC do every the [indiscernible] you

Ron Cooper

exactly know Yes, We be good question, honest. don't Katherine. to

the is diseases. that I one multiple number thing liver to we're committed generating data think across cholestatic that

of that once with we get And physicians product. sit as well prescribing opinion of probably understand designs. be some think and we'll But on really advisory for as guess down want provide because we'll for with that particular do discussions would data potential leaders our feedback, agency is it patients key their this types and the now to of in are very study true my combination I We of group will much the things, feedback. heavy right those we'll be get as what possible

Katherine Xu

Thank you very much.

Ron Cooper

Thanks, Katherine.

Operator

from question Our comes proceed Capital. Please with Yasmeen ROTH next Rahimi your with question.

Yasmeen Rahimi

done I one market then where in question has been decks? for of in elaborate the your sort of a -- have some recent a relationship while follow-up slide you little Ron, and can of find to bit team. a [indiscernible] research that the we Hi, have of disclosed you, this question. can terms pricing you comparisons this in market information, then And this more

Ron Cooper

right. All Thank you, Yasmeen.

terms very earlier of research. in amounts market research, had done of little we market So

so heavy part we've the And first gone this year. of pretty in

research, secondary given PFIC has range which medical the of market that we've So a we That a it's research. We've pricing and done some benchmark that relief, well. research ultra and benefit previously think full And on a demonstrate quantitative has for that we've more some done done need. disease, I that given we've we've those $XXX,XXX ultra-orphan between long-term symptomatic journey. products patient as -- $XXX,XXX hope qualitative done market somewhere but what because research, some us was insight are high-end The to rare. a year and said

a that Now, last done, is the that things But moving over we one click investors has there's recently corporate because time. the of there. our the find information a and of same can our changed more presentation corporate year, things lot updated you others the presentation lot are to we've and the Yasmeen, there section website right you if and our on bottom at in

Yasmeen Rahimi

mind, week study with can us to you, And in bit that that XXX, some can And their a made you discontinue versus maybe you why that that have elaborate again insight then and last more, elobixibat ICXX they in of remind of they're maybe decided discontinuing Shire Thank NASH. you announcement XXX the Ron. little the trial?

Ron Cooper

Yasmeen. well, thanks much, Okay, very

more. back. and a XX this acids think now. And let Jan in for few I is years and been others sort bile our me of comments make step then ask a have sort that team of Jan over add a I'll scientific to in working bit listen, well

a we're right inhibitors. compounds. inhibitors inhibitor differently, that's even understanding our dose why that's we are disease. and elobixibat different population, inhibitors, of the why we're of IBAT and pretty pretty right two they're about have right specifically They're so, how right you about… we doing both we're but what why with act Jan, think disease AXXXX fitting bit for the I at the and They right And confident the a IBAT to compounds. put right excited add maybe and want in IBAT patient agent to little IBAT have So good different the the tried we're

Jan Mattsson

Sure.

we selective, acting very the potent, rationale As really drug. locally highly NASH. you are and said, for it's elobixibat on confident elobixibat, in And

SHPXXX, And bile Now, inflammation heavily, increased we the the of on of we I potent preclinical ten X, field I of the comparing discussed before, the with important. I with showing NASH have times the a very fibrosis. the GLP data bile to as about. have we the more are compound, But as effects associated I increase lot before, acids on have lowering, data think in we really is moving [indiscernible] clinical think have that [indiscernible] think, elobixibat acids and data said showing the is showing of

I So we're confident. think

Ron Cooper

you, Thank Jan.

Yasmeen Rahimi

Jan. the validation that Liver submitted the some to you, guys doing One pruritus any Thank last the are to of guys in in question, Meeting work abstracts measure? with of you have The relation you regards upcoming,

Ron Cooper

So two meetings in U.S., the there's really fall AASLD [indiscernible]. in the there and are

to We as other Plus, some are meetings. well. putting groups are some there both those of have together content submissions of independent that the made

that we get you let as we'll to So closer know.

Yasmeen Rahimi

taking questions. you for Thank my

Operator

Our Company. your with Carr with from Please Needham next Alan question question. comes proceed &

Alan Carr

in U.S., substantially. the or you prevalence And wanted changed in And to you Europe my X,XXX wondering taking X,XXX, for I X,XXX if that's had questions. of patients. previously a bit PFIC I'm around maybe said thanks clarify so. around Hi,

on and the prevalence with Can it in elaborate of you on your going PFIC. if could going in bundled Phase on more in on parallel estimate of I non-clinical Thanks. touched parallel also bit newest wondered BRIC, work. breakout that's then some work what's to a you X And you area? you side think I that, think that your the

Ron Cooper

first, for question. answer the Good Maybe to Thanks, second quick morning, one Alan. just that. it's a taking thanks your

a you place. that to you standard you in have As things do need filing some have

need And in your standard And long-term they studies place. stock your time preclinical to they are such and repo right, studies, some talk of studies. take cancer be do, study as to those

should all for wanted planned, fact those items they all They're And and so gating just our you in let going. to filing. and that up are proceeding be as know not

questions sort our ensure about I just So X as about Obviously, move starting the data it to literature in of we filing, product. that Then not and PEDFIC-X, effective but the to towards commercialization the to translate of thinking do that over strong package a do said Phase the thinking best when secondary we're there not. PFIC, prevalence comment, your literature then been our indicates to study, but we've are as how prevalence prepared resources. as in the able regards were of or we're to my there overall that using published prefer that's the we that on time that's And I there. longest for think, will if registries, there was we

a some with prevalence that And what curve. has overall that believe difference thinking from adjust on our us primary strengthen market to getting makes survival we able the big research insights particularly been have the picture of We had perspective.

XX,XXX where more guidance previously little mix to then, -- XX,XXX total within XX,XXX. end different. we've to now gotten have to was But given insights, the that XX,XXX as have that to similar around relates now cholestatic that But to XXXX guidance population. to insights is now we XX,XXX our getting we liver to XXXX in our but we XX,XXX XXXX greater So at -- estimate. the given guided top XX,XXX, bit it a the we've disease as to narrowed PFIC, And on have somewhere

it half that So, roughly half think is of and of about PFIC about that BRIC. is

the BRIC and is part Now PFIC. different same what BRIC, this of BRIC what is parts versus reminds is you of

same is biggest the of manifestation manner most kids episodic. difference genes the Probably the are of the the disease very time. pleuritis though on get category, PFIC in as same treated patients. terms also often So occur itself clinical it's the PFIC similar severe same is the that and in These in of

So, about average or episode one months. at least a five more. It patients year have to BRIC tend lasts on

it's So intermittent.

is in difference for result it's we estimated And estimate of XX now the right XX. about with as other So the treatment BRIC, around is years. survival. a PFIC children difference current --

then getting summarize So then to -- numbers. back sort the of to

So Europe think research. think BRIC. XXXX the same; then half PFIC half half about pretty the much about U.S., to in recent based And our U.S. physician the and the about Europe XX,XXX is on in and

Alan Carr

Okay. my for Thanks talking questions.

Ron Cooper

Alan. Thanks,

Operator

Instructions] your Liana from with comes [Operator Please Moussatos with next Securities. Wedbush Our proceed question question.

Liana Moussatos

your about What NASH. of wondering Phase my thinking and about progress are for on am taking the for question. and you Congratulations for X primary I design elobixibat endpoint?

Ron Cooper

Liana. you question, comments, Thank for thank you for the the and

still finalized So on proof-of-concept for as a more study as I a -- It's of towards leaning strong yet. that. [ph] PDFF think as this type mechanism working But we the are that process not But hasn't add about want spending to the to now I we really refine don't in endpoint. you Right time with if leaders been know are that. our of opinion yet. any… key finalized think

Jan Mattsson

we'll right. mean are that's guide think the guess I I in good very we this and discussions -- I will [indiscernible] later. with I on

Ron Cooper

the we kind Liana, whole with leaders the we program locked kind plan down once regulators, somewhere key will of walk comfortable Yes, think I later through and on, we the have is you. on with to opinion our of for are later

Liana Moussatos

Okay. very Thank you much.

Operator

the time, turn call to to this At would over you. Cooper Thank remark. Ron for I closing back like

Ron Cooper

you very thank All Operator, right, much.

First of thanks tuning everybody for all, in.

a last quarter. we think that this in progress made I lot of

for summer. Bye-bye. of wishing all, end terrific know, the the all you a So, best you

Operator

conference. gentlemen. Thank conclude This you, does ladies today's and

lines day. your a this disconnect great and may at time, have You

Albireo Pharma (ALBO) 7 Aug 182018 Q2 Earnings call transcript